Lavipharm Past Earnings Performance
Past criteria checks 4/6
Lavipharm's earnings have been declining at an average annual rate of -22.3%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 9.5% per year. Lavipharm's return on equity is 4.7%, and it has net margins of 3.9%.
Key information
-22.3%
Earnings growth rate
-24.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 9.5% |
| Return on equity | 4.7% |
| Net Margin | 3.9% |
| Next Earnings Update | 23 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Lavipharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 51 | 2 | 19 | 0 |
| 30 Sep 23 | 54 | 0 | 16 | 1 |
| 30 Jun 23 | 54 | 1 | 17 | 1 |
| 31 Mar 23 | 49 | 1 | 16 | 1 |
| 31 Dec 22 | 39 | 1 | 15 | 1 |
| 30 Sep 22 | 43 | 2 | 4 | 0 |
| 30 Jun 22 | 41 | 1 | 15 | 1 |
| 31 Mar 22 | 41 | 1 | 12 | 1 |
| 31 Dec 21 | 40 | 2 | 15 | 1 |
| 30 Sep 21 | 39 | 2 | 15 | 1 |
| 30 Jun 21 | 39 | 3 | 14 | 1 |
| 31 Mar 21 | 38 | 2 | 14 | 1 |
| 31 Dec 20 | 38 | 2 | 14 | 1 |
| 30 Sep 20 | 37 | 4 | 14 | 1 |
| 30 Jun 20 | 36 | 7 | 14 | 1 |
| 31 Mar 20 | 35 | 6 | 14 | 1 |
| 31 Dec 19 | 34 | 5 | 14 | 1 |
| 30 Sep 19 | 34 | 3 | 14 | 1 |
| 30 Jun 19 | 34 | 1 | 14 | 1 |
| 31 Mar 19 | 34 | 1 | 15 | 1 |
| 31 Dec 18 | 34 | 1 | 15 | 1 |
| 30 Sep 18 | 33 | 0 | 16 | 1 |
| 30 Jun 18 | 32 | -1 | 16 | 1 |
| 31 Mar 18 | 32 | 6 | 16 | 1 |
| 31 Dec 17 | 32 | 13 | 15 | 2 |
| 30 Sep 17 | 32 | 11 | 17 | 2 |
| 30 Jun 17 | 32 | 10 | 18 | 2 |
| 31 Mar 17 | 32 | 7 | 18 | 2 |
| 31 Dec 16 | 31 | 4 | 18 | 3 |
| 30 Sep 16 | 31 | 4 | 18 | 3 |
| 30 Jun 16 | 28 | 4 | 15 | 3 |
| 31 Mar 16 | 27 | -2 | 15 | 3 |
| 31 Dec 15 | 26 | -7 | 15 | 3 |
| 30 Sep 15 | 27 | -9 | 15 | 4 |
| 30 Jun 15 | 29 | -9 | 17 | 4 |
| 31 Mar 15 | 30 | -26 | 16 | 4 |
| 31 Dec 14 | 30 | -26 | 17 | 4 |
| 30 Sep 14 | 28 | -23 | 15 | 3 |
| 30 Jun 14 | 29 | -24 | 16 | 3 |
| 31 Mar 14 | 29 | -7 | 16 | 2 |
| 31 Dec 13 | 30 | -8 | 17 | 2 |
| 30 Sep 13 | 34 | -7 | 18 | 2 |
| 30 Jun 13 | 35 | -7 | 19 | 2 |
Quality Earnings: LAVI has a large one-off gain of €889.0K impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: LAVI's current net profit margins (3.9%) are higher than last year (2.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LAVI has become profitable over the past 5 years, growing earnings by -22.3% per year.
Accelerating Growth: LAVI's earnings growth over the past year (109.7%) exceeds its 5-year average (-22.3% per year).
Earnings vs Industry: LAVI earnings growth over the past year (109.7%) exceeded the Pharmaceuticals industry 2.6%.
Return on Equity
High ROE: LAVI's Return on Equity (4.7%) is considered low.